Novel orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium

CONTEXT: Uterine leiomyomas are highly prevalent and often symptomatic. Current medical therapies are limited. A novel, potent, selective, orally active therapy is needed. OBJECTIVE AND METHODS: To determine the progesterone receptor (PR) specificity and activation, endometrial response, and impact...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Catherino, William H., Malik, Minnie, Driggers, Paul, Chappel, Scott, Segars, James, Davis, Joseph
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3576019/
https://ncbi.nlm.nih.gov/pubmed/20493256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsbmb.2010.05.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky